Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dumpster the Day Trading Guru - 5x5 = 25%
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(450)
•••
Comment by davgroon Jun 02, 2022 1:13pm
111 Views
Post# 34726996

RE:RE:Dumpster the Day Trading Guru - 5x5 = 25%

RE:RE:Dumpster the Day Trading Guru - 5x5 = 25%
Duster340 wrote: having fun with house money.

$35 of house money (profit) ??  That doesn't even buy a good lunch at a restaurant these days.  And Dumpster, why can't you even be honest about your trades ?  You said you sold at $0.23 but you actually sold 3000 of the 6000 shares at $0.225.  I can see your trades:

12:35:20 A 0.225 0.005 3,000 79 CIBC 124 Questrade K
12:26:34 V 0.23 0.01 3,000 84 Ind Trading 124 Questrade K

Now if you bought at $0.22 your profit wasn't $35 but $25 as you didn't take into account your initial commission of $9.99 to buy the 6000 shares.  Just keeping you honest.  Prove me wrong.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities